Data on new Novo Nordisk obesity drug disappoints in trial, shares drop
Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate CagriSema, knocking shares and stoking worries that rival Eli Lilly may be gaining an edge over the company in the weight-loss drugs market.
Semaglutide and tirzepatide confer greater improvements in life expectancy than naltrexone/bupropion and ...
Anti-obesity drugs are only part of the larger treatment plan for most patients. Exercise and nutrition are also keys.
Germany's financial markets watchdog is looking at whether Bayer fairly disclosed plans for shareholder approval of a capital ...
Anyone who has tried to lose weight by cutting calories knows the frustration—after initial success, weight loss slows down ...
Professor Arne Astrup is also involved in project to change widely-accepted definition of ultra-processed food ...
NSYNC entertainer diagnosed with rare form of diabetes that happens in adulthood but is more like Type 1 than Type 2.
Obesity has long been classified as a global epidemic — and new data published in The Lancet journal spotlights how much ...
World Obesity Day, observed on March 4th, emphasizes the dangers of the combined effects of diabetes and obesity, termed ...
News-Medical.Net on MSN2d
Tirzepatide helps people without diabetes lose 13% body weight in real-world studyA real-world study of over 4,000 US patients without type 2 diabetes found that those who persisted with Tirzepatide for at ...
Altimmune said on Thursday that it plans to test its lead experimental obesity drug, pemvidutide, to potentially treat ...
By being educated about the risks associated with obesity and pregnancy, you can take some powerful steps today to begin ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback